Research Reports

Key takeaways

Darren Snellgrove appointed CFO effective June 8, 2026, succeeding interim CFO David Ramsay who transitions to advisory role.

Snellgrove brings 27 years at Johnson & Johnson, including recent VP Investor Relations and prior CFO of J&J Pharmaceuticals sector.

Annual base salary of $670,000; 50% target bonus prorated for 2026.

Sign-on cash bonus of $350,000 subject to partial repayment clawback if terminates early or for cause.

New-hire equity: $3.2M RSUs (make-whole for forfeited J&J equity) and $4.0M stock options under 2021 Stock Plan.

2027 long-term incentive award minimum $4.0M grant date value.

Full analysis

Halozyme's appointment of Darren Snellgrove as permanent CFO signals a strategic leadership enhancement, bringing proven financial expertise from Johnson & Johnson where he managed a $50 billion pharmaceuticals sector and led investor relations. The Compensation Committee structured his package competitively to offset forfeited J&J equity and cash, aligning with pay-for-performance via performance-based stock options while providing immediate RSU value. This move ensures continuity as interim CFO David Ramsay aids transition, positioning Halozyme to advance its ENHANZE drug delivery technology and portfolio expansion amid growth opportunities.

HALO · Halozyme Therapeutics, Inc.

Summary

Key takeaways

Full analysis